In January 2024, the State Food and Drug Administration officially approved the import of the nine-valent human papillomavirus vaccine. The top three high-risk HPV subtypes that Chinese women are most susceptible to are: HPV16, HPV52, and HPV58.

The HPV infection rate shows a "bimodal" distribution by age, with the first peak of infection in "17-24 years old" and the second peak in "40-44 years old". Completing HPV vaccination for teenage girls before the age of 15 is one of the keys to eliminating cervical cancer.